{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:22:58Z","timestamp":1788780178613,"version":"build-2803163510"},"reference-count":120,"publisher":"Oxford University Press (OUP)","issue":"15","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000860","name":"European Society of Cardiology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000860","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cardiovascular diseases (CVD) remain the leading cause of death globally and there is an urgent need for innovative approaches to treatment. One emerging avenue is genetic therapies, which hold particular promise for diseases with a monogenic basis. Gene silencing techniques using antisense oligonucleotides or ribonucleic acid interference strategies are currently at the forefront of genetic therapies in CVD, with several ribonucleic acid-targeted therapies already approved for the treatment of conditions such as familial hypercholesterolaemia and transthyretin amyloidosis. For diseases caused by loss-of-function genetic variants, there is growing interest in gene therapy, applying either gene replacement strategies using adeno-associated virus vectors or gene editing strategies using tools such as the clustered regularly interspaced short palindromic repeats and clustered regularly interspaced short palindromic repeats-associated protein-9 system. Preclinical studies have highlighted the potential of this technology in CVD and promising data are beginning to emerge from early-phase clinical trials. During a European Society of Cardiology Cardiovascular Round Table workshop, the challenges of translating these novel therapeutic strategies to the routine cardiology clinic were discussed. Several key priorities were identified, including the need for disease-specific preclinical models, precision diagnostics, adequately powered clinical trials with meaningful endpoints, and enhanced education of healthcare professionals and patients. The Cardiovascular Round Table also considered the role of polygenic risk scores in risk stratification and how these can potentially be implemented in clinical practice.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehaf041","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:39:56Z","timestamp":1739972396000},"page":"1384-1393","source":"Crossref","is-referenced-by-count":7,"title":["Translation of genomics into routine cardiological practice: insights from a European Society of Cardiology Cardiovascular Round Table"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1045-2436","authenticated-orcid":false,"given":"Stefanie","family":"Dimmeler","sequence":"first","affiliation":[{"name":"Institute of Cardiovascular Regeneration, Goethe University , Frankfurt ,","place":["Germany"]},{"name":"Cardiopulmonary Institute , Frankfurt ,","place":["Germany"]},{"name":"German Center for Cardiovascular Research (DZHK), Partner Site RheinMain , Frankfurt ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Ferri","sequence":"additional","affiliation":[{"name":"AstraZeneca , Wilmington, DE ,","place":["USA"]},{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nioi","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals , Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Novartis Biomedical Research , Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-3848","authenticated-orcid":false,"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Referral Center for Cardiac Amyloidosis , H\u00f4pital Henri-Mondor, AP-HP, 94000 Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"G\u00f3mez-Outes","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Clinical Drug Evaluation, Medicines for Human Use, Spanish Agency for Medicines and Healthcare Products (AEMPS) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2927-7225","authenticated-orcid":false,"given":"Mauro","family":"Giacca","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical, and Health Sciences, University of Trieste and International Center for Genetic Engineering and Biotechnology (ICGEB) , Trieste ,","place":["Italy"]},{"name":"King's College London, British Heart Foundation Center of Research Excellence, School of Cardiovascular Medicine & Sciences , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weinong","family":"Guo","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals , Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5976-6519","authenticated-orcid":false,"given":"Maryam","family":"Kavousi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Erasmus MC University Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-7275","authenticated-orcid":false,"given":"Christian","family":"Kupatt","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Innere Medizin I, Klinikum rechts der Isar, Technical University Munich , Munich ,","place":["Germany"]},{"name":"Deutsches Zentrum f\u00fcr Herz- und Kreislauferkrankungen (DZHK), Partner Site Munich Heart Alliance , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum der Charit\u00e9, Campus Benjamin Franklin, Klinik f\u00fcr Kardiologie, Angiologie und Intensivmedizin , Berlin ,","place":["Germany"]},{"name":"DZHK, German Centre for Cardiovascular Research , Partner Site, Berlin ,","place":["Germany"]},{"name":"Friede Springer Cardiovascular Prevention Center at Charit\u00e9, Charit\u00e9 University Medicine Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6428-3001","authenticated-orcid":false,"given":"Heribert","family":"Schunkert","sequence":"additional","affiliation":[{"name":"Deutsches Zentrum f\u00fcr Herz- und Kreislauferkrankungen (DZHK), Partner Site Munich Heart Alliance , Munich ,","place":["Germany"]},{"name":"Department of Cardiology, Deutsches Herzzentrum M\u00fcnchen, Technische Universit\u00e4t M\u00fcnchen , Lazarettstr. 36, Munich 80636 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Zouridakis","sequence":"additional","affiliation":[{"name":"UK Medicines & Healthcare Products Regulatory Agency , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3383-3984","authenticated-orcid":false,"given":"Perry M","family":"Elliott","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science and British Heart Foundation Centre of Research Excellence, University College London , Rayne Institute, 5 University St, London WC1E 6JF ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"2025041508413878300_ehaf041-B1","doi-asserted-by":"publisher","first-page":"e078523","DOI":"10.1136\/bmj-2023-078523","article-title":"Trends in cardiovascular disease incidence among 22 million people in the UK over 20 years: population based study","volume":"385","author":"Conrad","year":"2024","journal-title":"BMJ"},{"key":"2025041508413878300_ehaf041-B2","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the global burden of disease study 2017","volume":"392","author":"GBD 2017 Causes of Death Collaborators","year":"2018","journal-title":"Lancet"},{"key":"2025041508413878300_ehaf041-B3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11886-021-01540-0","article-title":"Monogenic and polygenic models of coronary artery disease","volume":"23","author":"Muse","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"2025041508413878300_ehaf041-B4","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001077","article-title":"Polygenic risk scores for cardiovascular disease: a scientific statement from the American Heart Association","volume":"146","author":"O'Sullivan","year":"2022","journal-title":"Circulation"},{"key":"2025041508413878300_ehaf041-B5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jacc.2020.06.037","article-title":"Identification of undetected monogenic cardiovascular disorders","volume":"76","author":"Abdulrahim","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025041508413878300_ehaf041-B6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3390\/pharmaceutics15010260","article-title":"What can RNA-based therapy do for monogenic diseases?","volume":"15","author":"Clarke","year":"2023","journal-title":"Pharmaceutics"},{"key":"2025041508413878300_ehaf041-B7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jgg.2023.08.001","article-title":"Gene therapy for monogenic disorders: challenges, strategies, and perspectives","volume":"51","author":"Zhang","year":"2024","journal-title":"J Genet Genomics"},{"key":"2025041508413878300_ehaf041-B8","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/joim.13362","article-title":"Genetics of coronary artery disease in the post-GWAS era","volume":"290","author":"Chen","year":"2021","journal-title":"J Intern Med"},{"key":"2025041508413878300_ehaf041-B9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCRESAHA.120.316575","article-title":"Genetics of atrial fibrillation in 2020: GWAS, genome sequencing, polygenic risk, and beyond","volume":"127","author":"Roselli","year":"2020","journal-title":"Circ Res"},{"key":"2025041508413878300_ehaf041-B10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000496150","article-title":"Genome-wide association studies of hypertension and several other cardiovascular diseases","volume":"6","author":"Wang","year":"2019","journal-title":"Pulse (Basel)"},{"key":"2025041508413878300_ehaf041-B11","doi-asserted-by":"publisher","first-page":"818574","DOI":"10.3389\/fgene.2022.818574","article-title":"Calculating polygenic risk scores (PRS) in UK Biobank: a practical guide for epidemiologists","volume":"13","author":"Collister","year":"2022","journal-title":"Front Genet"},{"key":"2025041508413878300_ehaf041-B12","first-page":"1372","article-title":"Clinical utility and implementation of polygenic risk scores for predicting cardiovascular disease","volume":"46","author":"Schunkert","year":"2025","journal-title":"Eur Heart J"},{"key":"2025041508413878300_ehaf041-B13","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1016\/S0140-6736(14)61730-X","article-title":"Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials","volume":"385","author":"Mega","year":"2015","journal-title":"Lancet"},{"key":"2025041508413878300_ehaf041-B14","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1161\/CIRCULATIONAHA.119.043805","article-title":"Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score: results from the FOURIER trial","volume":"141","author":"Marston","year":"2020","journal-title":"Circulation"},{"key":"2025041508413878300_ehaf041-B15","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/CIR.0000000000000678","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"2025041508413878300_ehaf041-B16","doi-asserted-by":"publisher","first-page":"e013296","DOI":"10.1161\/JAHA.119.013296","article-title":"ST-segment-elevation myocardial infarction (STEMI) patients without standard modifiable cardiovascular risk factors\u2014how common are they, and what are their outcomes?","volume":"8","author":"Vernon","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2025041508413878300_ehaf041-B17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41569-021-00638-w","article-title":"Clinical utility of polygenic risk scores for coronary artery disease","volume":"19","author":"Klarin","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2025041508413878300_ehaf041-B18","doi-asserted-by":"publisher","first-page":"I181","DOI":"10.1093\/eurheartjsupp\/suac091","article-title":"Polygenic risk score and age: an extra help in the cardiovascular prevention of the young?","volume":"24","author":"Temporelli","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"2025041508413878300_ehaf041-B19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11883-021-00915-6","article-title":"How do we incorporate polygenic risk scores in cardiovascular disease risk assessment and management?","volume":"23","author":"Hadley","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"2025041508413878300_ehaf041-B20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00392-022-02081-4","article-title":"Genetic and modifiable risk factors combine multiplicatively in common disease","volume":"112","author":"Pang","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2025041508413878300_ehaf041-B21","doi-asserted-by":"publisher","first-page":"e000554","DOI":"10.1136\/bmjmed-2023-000554","article-title":"Performance of polygenic risk scores in screening, prediction, and risk stratification: secondary analysis of data in the polygenic score catalog","volume":"2","author":"Hingorani","year":"2023","journal-title":"BMJ Med"},{"key":"2025041508413878300_ehaf041-B22","doi-asserted-by":"publisher","first-page":"e1003498","DOI":"10.1371\/journal.pmed.1003498","article-title":"Polygenic risk scores in cardiovascular risk prediction: a cohort study and modelling analyses","volume":"18","author":"Sun","year":"2021","journal-title":"PLoS Med"},{"key":"2025041508413878300_ehaf041-B23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jamacardio.2022.4466","article-title":"Predictive utility of a coronary artery disease polygenic risk score in primary prevention","volume":"8","author":"Marston","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2025041508413878300_ehaf041-B24","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1093\/eurheartj\/ehae048","article-title":"Integration of a polygenic score into guideline-recommended prediction of cardiovascular disease","volume":"45","author":"Li","year":"2024","journal-title":"Eur Heart J"},{"key":"2025041508413878300_ehaf041-B25","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3399\/bjgp22X720437","article-title":"Polygenic risk scores: improving the prediction of future disease or added complexity?","volume":"72","author":"Ayoub","year":"2022","journal-title":"Br J Gen Pract"},{"key":"2025041508413878300_ehaf041-B26","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1093\/eurheartj\/ehae342","article-title":"Polygenic risk score adds to a clinical risk score in the prediction of cardiovascular disease in a clinical setting","volume":"45","author":"Samani","year":"2024","journal-title":"Eur Heart J"},{"key":"2025041508413878300_ehaf041-B27","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","article-title":"Clinical use of current polygenic risk scores may exacerbate health disparities","volume":"51","author":"Martin","year":"2019","journal-title":"Nat Genet"},{"key":"2025041508413878300_ehaf041-B28","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41591-023-02429-x","article-title":"A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease","volume":"29","author":"Patel","year":"2023","journal-title":"Nat Med"},{"key":"2025041508413878300_ehaf041-B29","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/s41588-020-0705-3","article-title":"Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease","volume":"52","author":"Koyama","year":"2020","journal-title":"Nat Genet"},{"key":"2025041508413878300_ehaf041-B30","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/HCO.0000000000000850","article-title":"RNA therapeutics for cardiovascular disease","volume":"36","author":"Boada","year":"2021","journal-title":"Curr Opin Cardiol"},{"key":"2025041508413878300_ehaf041-B31","doi-asserted-by":"publisher","first-page":"618346","DOI":"10.3389\/fgeed.2021.618346","article-title":"The promise and the hope of gene therapy","volume":"3","author":"Papanikolaou","year":"2021","journal-title":"Front Genome Ed"},{"key":"2025041508413878300_ehaf041-B32","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.rec.2023.06.009","article-title":"Gene therapy for heart failure and cardiomyopathies","volume":"76","author":"Argir\u00f2","year":"2023","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2025041508413878300_ehaf041-B33","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41419-022-05075-2","article-title":"RNA-based therapeutics: an overview and prospectus","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis"},{"key":"2025041508413878300_ehaf041-B34","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab"},{"key":"2025041508413878300_ehaf041-B35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol Pathol"},{"key":"2025041508413878300_ehaf041-B36","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3389\/fgene.2020.01020","article-title":"PCSK9 variants in familial hypercholesterolemia: a comprehensive synopsis","volume":"11","author":"Guo","year":"2020","journal-title":"Front Genet"},{"key":"2025041508413878300_ehaf041-B37","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"2025041508413878300_ehaf041-B38","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s11886-022-01782-6","article-title":"PCSK9 inhibitor wars: how does inclisiran fit in with current monoclonal antibody inhibitor therapy? Considerations for patient selection","volume":"24","author":"Arnold","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"2025041508413878300_ehaf041-B39","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2025041508413878300_ehaf041-B40","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"2025041508413878300_ehaf041-B41","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025041508413878300_ehaf041-B42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025041508413878300_ehaf041-B43","author":"ClinicalTrials.gov"},{"key":"2025041508413878300_ehaf041-B44","author":"ClinicalTrials.gov"},{"key":"2025041508413878300_ehaf041-B45","author":"ClinicalTrials.gov"},{"key":"2025041508413878300_ehaf041-B46","doi-asserted-by":"publisher","first-page":"3491764","DOI":"10.1155\/2020\/3491764","article-title":"Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule","volume":"2020","author":"Jawi","year":"2020","journal-title":"J Lipids"},{"key":"2025041508413878300_ehaf041-B47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40119-024-00353-w","article-title":"Targeting lipoprotein(a): can RNA therapeutics provide the next step in the prevention of cardiovascular disease?","volume":"13","author":"Thau","year":"2024","journal-title":"Cardiol Ther"},{"key":"2025041508413878300_ehaf041-B48","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s11886-013-0396-9","article-title":"Genetics of lipid traits and relationship to coronary artery disease","volume":"15","author":"Keenan","year":"2013","journal-title":"Curr Cardiol Rep"},{"key":"2025041508413878300_ehaf041-B49","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"2025041508413878300_ehaf041-B50","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"2025041508413878300_ehaf041-B51","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"2025041508413878300_ehaf041-B52","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"2025041508413878300_ehaf041-B53","author":"ClinicalTrials.gov"},{"key":"2025041508413878300_ehaf041-B54","author":"ClinicalTrials.gov"},{"key":"2025041508413878300_ehaf041-B55","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11883-021-00914-7","article-title":"ANGPTL3 and apolipoprotein C-III as novel lipid-lowering targets","volume":"23","author":"Akoumianakis","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"2025041508413878300_ehaf041-B56","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"2025041508413878300_ehaf041-B57","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"key":"2025041508413878300_ehaf041-B58","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025041508413878300_ehaf041-B59","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"key":"2025041508413878300_ehaf041-B60","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"2025041508413878300_ehaf041-B61","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N Engl J Med"},{"key":"2025041508413878300_ehaf041-B62","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2025041508413878300_ehaf041-B63","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","article-title":"RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts","volume":"29","author":"Watts","year":"2023","journal-title":"Nat Med"},{"key":"2025041508413878300_ehaf041-B64","doi-asserted-by":"publisher","first-page":"A17120","DOI":"10.1161\/circ.148.suppl_1.17120","article-title":"ARO-ANG3, an investigational RNAi therapeutic, silences the expression of ANGPTL3 and decreases atherogenic lipoproteins in patients with mixed dyslipidemia: ARCHES-2 study results","volume":"148","author":"Watts","year":"2023","journal-title":"Circulation"},{"key":"2025041508413878300_ehaf041-B65","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0735-1097(24)03663-5","article-title":"Solbinsiran, a galnac-conjugated siRNA targeting ANGPTL3, reduces atherogenic lipoproteins in individuals with mixed dyslipidaemia in a durable and dose dependent manner","volume":"83","author":"Ray","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025041508413878300_ehaf041-B66","author":"ClinicalTrials.gov"},{"key":"2025041508413878300_ehaf041-B67","author":"ClinicalTrials.gov"},{"key":"2025041508413878300_ehaf041-B68","author":"ClinicalTrials.gov"},{"key":"2025041508413878300_ehaf041-B69","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40259-023-00577-7","article-title":"RNA targeting and gene editing strategies for transthyretin amyloidosis","volume":"37","author":"Ioannou","year":"2023","journal-title":"Biodrugs"},{"key":"2025041508413878300_ehaf041-B70","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.3390\/ijms22094429","article-title":"Transthyretin misfolding, a fatal structural pathogenesis mechanism","volume":"22","author":"Si","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025041508413878300_ehaf041-B71","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.3390\/jcm11082148","article-title":"Treatment of transthyretin amyloid cardiomyopathy: the current options, the future, and the challenges","volume":"11","author":"Tsch\u00f6pe","year":"2022","journal-title":"J Clin Med"},{"key":"2025041508413878300_ehaf041-B72","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10741-023-10380-9","article-title":"Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy","volume":"29","author":"Wu","year":"2024","journal-title":"Heart Fail Rev"},{"key":"2025041508413878300_ehaf041-B73","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2025041508413878300_ehaf041-B74","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: first global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"2025041508413878300_ehaf041-B75","author":"Alnylam Pharmaceuticals Inc"},{"key":"2025041508413878300_ehaf041-B76","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"2025041508413878300_ehaf041-B77","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"2025041508413878300_ehaf041-B78","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"2025041508413878300_ehaf041-B79","author":"Alnylam Pharmaceuticals Inc"},{"key":"2025041508413878300_ehaf041-B80","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"2025041508413878300_ehaf041-B81","author":"Alnylam Pharmaceuticals Inc"},{"key":"2025041508413878300_ehaf041-B82","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"2025041508413878300_ehaf041-B83","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","article-title":"Inotersen: first global approval","volume":"78","author":"Keam","year":"2018","journal-title":"Drugs"},{"key":"2025041508413878300_ehaf041-B84","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid"},{"key":"2025041508413878300_ehaf041-B85","author":"ClinicalTrials.gov"},{"key":"2025041508413878300_ehaf041-B86","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ehf2.13154","article-title":"Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data","volume":"8","author":"Viney","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2025041508413878300_ehaf041-B87","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-024-02008-5","article-title":"Eplontersen: first approval","volume":"84","author":"Nie","year":"2024","journal-title":"Drugs"},{"key":"2025041508413878300_ehaf041-B88","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"2025041508413878300_ehaf041-B89","author":"ClinicalTrials.gov"},{"key":"2025041508413878300_ehaf041-B90","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA interference therapeutic agent for hypertension","volume":"389","author":"Desai","year":"2023","journal-title":"N Engl J Med"},{"key":"2025041508413878300_ehaf041-B91","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jama.2024.0728","article-title":"RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial","volume":"331","author":"Bakris","year":"2024","journal-title":"JAMA"},{"key":"2025041508413878300_ehaf041-B92","author":"American College of Cardiology"},{"key":"2025041508413878300_ehaf041-B93","author":"ClinicalTrials.gov"},{"key":"2025041508413878300_ehaf041-B94","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1161\/CIRCRESAHA.114.302331","article-title":"Adeno-associated virus vectors as therapeutic and investigational tools in the cardiovascular system","volume":"114","author":"Zacchigna","year":"2014","journal-title":"Circ Res"},{"key":"2025041508413878300_ehaf041-B95","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.ymthe.2017.03.027","article-title":"Cardiovascular gene therapy: past, present, and future","volume":"25","author":"Yl\u00e4-Herttuala","year":"2017","journal-title":"Mol Ther"},{"key":"2025041508413878300_ehaf041-B96","doi-asserted-by":"publisher","first-page":"A11117","DOI":"10.1161\/circ.146.suppl_1.11117","article-title":"Phase 1 Danon disease results: the first single dose intravenous (IV) gene therapy (RP-A501) with recombinant adeno-associated virus (AAV9:LAMP2B) for a monogenic cardiomyopathy","volume":"146","author":"Rossano","year":"2022","journal-title":"Circulation"},{"key":"2025041508413878300_ehaf041-B97","author":"ClinicalTrials.gov"},{"key":"2025041508413878300_ehaf041-B98","author":"ClinicalTrials.gov"},{"key":"2025041508413878300_ehaf041-B99","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1093\/eurheartj\/ehae476","article-title":"KCNQ1 suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome","volume":"45","author":"Bains","year":"2024","journal-title":"Eur Heart J"},{"key":"2025041508413878300_ehaf041-B100","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1161\/CIRCULATIONAHA.120.051836","article-title":"Suppression-replacement KCNQ1 gene therapy for type 1 long QT syndrome","volume":"143","author":"Dotzler","year":"2021","journal-title":"Circulation"},{"key":"2025041508413878300_ehaf041-B101","author":"ClinicalTrials.gov"},{"key":"2025041508413878300_ehaf041-B102","author":"ClinicalTrials.gov"},{"key":"2025041508413878300_ehaf041-B103","doi-asserted-by":"publisher","first-page":"23484","DOI":"10.1161\/CIR.0000000000001200","article-title":"Phase 1 gene therapy trial in patients with advanced heart failure using a novel cardiotropic AAV vector targeting protein phosphatase inhibitor-1","volume":"148","author":"Henry","year":"2023","journal-title":"Circulation"},{"key":"2025041508413878300_ehaf041-B104","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.tcm.2020.06.008","article-title":"Translating genomic insights into cardiovascular medicine: opportunities and challenges of CRISPR-cas9","volume":"31","author":"Zhang","year":"2021","journal-title":"Trends Cardiovasc Med"},{"key":"2025041508413878300_ehaf041-B105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"2025041508413878300_ehaf041-B106","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models","volume":"147","author":"Lee","year":"2023","journal-title":"Circulation"},{"key":"2025041508413878300_ehaf041-B107","doi-asserted-by":"publisher","first-page":"23230","DOI":"10.1161\/CIR.0000000000001200","article-title":"Safety and pharmacodynamic effects of VERVE-101: an investigational DNA base editing medicine designed to durably inactivate the PCSK9 gene and lower LDL cholesterol \u2013 interim results of the phase 1b heart-1 trial","volume":"148","author":"Vafai","year":"2023","journal-title":"Circulation"},{"key":"2025041508413878300_ehaf041-B108","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/13543784.2024.2369747","article-title":"VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol","volume":"33","author":"Hooper","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"2025041508413878300_ehaf041-B109","author":"ClinicalTrials.gov"},{"key":"2025041508413878300_ehaf041-B110","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"2025041508413878300_ehaf041-B111","author":"ClinicalTrials.gov"},{"key":"2025041508413878300_ehaf041-B112","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1161\/CIRCRESAHA.120.318674","article-title":"Efficient correction of a hypertrophic cardiomyopathy mutation by ABEmax-NG","volume":"129","author":"Ma","year":"2021","journal-title":"Circ Res"},{"key":"2025041508413878300_ehaf041-B113","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1093\/cvr\/cvac021","article-title":"Gene editing reverses arrhythmia susceptibility in humanized PLN-R14del mice: modelling a European cardiomyopathy with global impact","volume":"118","author":"Dave","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2025041508413878300_ehaf041-B114","author":"European Medicines Agency"},{"key":"2025041508413878300_ehaf041-B115","volume-title":"Available from","author":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP)"},{"key":"2025041508413878300_ehaf041-B116","author":"European Medicines Agency"},{"key":"2025041508413878300_ehaf041-B117","author":"GOV.UK"},{"key":"2025041508413878300_ehaf041-B118","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/j.ymthe.2022.04.002","article-title":"Gene therapy access: global challenges, opportunities, and views from Brazil, South Africa, and India","volume":"30","author":"Cornetta","year":"2022","journal-title":"Mol Ther"},{"key":"2025041508413878300_ehaf041-B119","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/S2589-7500(23)00065-1","article-title":"Identifying subtypes of heart failure from three electronic health record sources with machine learning: an external, prognostic, and genetic validation study","volume":"5","author":"Banerjee","year":"2023","journal-title":"Lancet Digit Health"},{"key":"2025041508413878300_ehaf041-B120","author":"Our Future Health"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/15\/1384\/61977003\/ehaf041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/15\/1384\/61977003\/ehaf041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T08:41:42Z","timestamp":1744706502000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/15\/1384\/8023897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":120,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,2,19]]},"published-print":{"date-parts":[[2025,4,15]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf041","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4,14]]},"published":{"date-parts":[[2025,2,19]]}}}